Alien Insurer

An alien insurer, also known as a foreign insurer, is an insurance company that is formed and domiciled in a country other than the one in which it is conducting business. For example, a British insurance company that provides insurance coverage in the United States would be considered an alien insurer in the US.

Key features of alien insurers typically include:

  • Licensing and regulation: Alien insurers must be licensed and regulated in each country where they do business.

  • Financial strength: These insurers must have strong financial ratings and a solid reputation in the industry.

  • Market specialization: Many alien insurers specialize in specific types of insurance, such as marine insurance or aviation insurance.

  • Multilingual staff: Alien insurers often employ multilingual staff to communicate effectively with customers and business partners in different countries.

  • Compliance: Alien insurers must comply with the laws and regulations of each country in which they operate, including tax laws and reporting requirements.

  • Reinsurance: Alien insurers may use reinsurance to manage risk and ensure that they have the capacity to pay claims.

Overall, alien insurers play an important role in the global insurance industry, providing coverage to businesses and individuals in different countries and helping to manage risk across borders.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.